Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
12-14 August, 2025
Not Confirmed
Not Confirmed
17-21 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
12-14 August, 2025
Industry Trade Show
Not Confirmed
17-21 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
29 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-engagement-with-icon-and-expansion-of-phase-ii-clinical-trial-for-ht-001-in-europe-302515747.html
22 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hoth-therapeutics-signs-va-research-deal-to-advance-gdnf-as-breakthrough-therapy-for-obesity-and-fatty-liver--side-by-side-study-vs-semaglutide-begins-302510423.html
25 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-and-silo-pharma-nasdaq-silo-today-announced-the-formation-of-a-5050-joint-venture-to-develop-a-first-in-class-gdnf-based-therapy-licensed-from-the-us-department-of-veterans-affairs-the-therapy-targe-302490308.html
25 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/25/3105102/0/en/Silo-Pharma-Enters-into-Letter-of-Intent-to-Form-Joint-Venture-with-Hoth-Therapeutics-to-Develop-Obesity-Treatment-Targeting-16-Billion-Global-Market.html
24 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hoth-therapeutics-ht-001-interim-results-first-in-class-topical-therapy-preserves-cancer-treatment-while-resolving-dermatologic-side-effects-302489805.html
23 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hoth-therapeutics-to-host-kol-event-spotlighting-ht-001-novel-therapy-302487954.html
ABOUT THIS PAGE